Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 5-18, January 2010

What Does the Generalist Need to Know About HIV Infection?

  • Joel E. Gallant

      Affiliations

    • Corresponding Author InformationAddress correspondence to Joel E. Gallant, MD, MPH, Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 443, Baltimore, MD 21205.

Department of Medicine and Epidemiology, Johns Hopkins University School of Medicine, Baltimore, MD

Despite recent improvements in the efficacy, safety, tolerability, and convenience of antiretroviral therapy for patients, the management of HIV infection remains complex for clinicians. Multiple studies have shown better clinical outcomes and lower cost of care when HIV-infected patients are managed by experts. However, generalists are frequently involved in the care of patients with HIV infection, in many cases providing primary care in collaboration with an HIV expert. Generalists also play a critical role in the diagnosis and prevention of HIV infection. Generalists managing HIV-infected patients should be aware of the components of the initial patient evaluation. They should be familiar with the general principles of antiretroviral therapy and opportunistic infection prevention. They should be able to recognize antiretroviral toxicity and should be aware of common drug-drug interactions involving antiretroviral agents.

Key Words: HIV, Antiretroviral therapy, Primary care, Expertise

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 In the last 12 months, Dr Gallant has served on advisory boards, data safety monitoring boards, or as a consultant for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Japan Tobacco, Koronis, Merck, Monogram Biosciences, Pfizer, RAPID Pharmaceuticals, Tibotec, and VIRxSYS. Johns Hopkins University has received research funding from Roche for clinical research being conducted by Dr. Gallant. Dr. Gallant does not have stock holdings in pharmaceutical companies and is not a member of any speakers' bureaus.

PII: S1548-5595(09)00158-X

doi:10.1053/j.ackd.2009.08.003

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 5-18, January 2010